Takeda Clears Last U.S. Court Hurdle To Save Actos Patent
This article was originally published in PharmAsia News
Takeda Pharmaceutical said the U.S. Supreme Court has ruled in its favor in a patent case involving its Actos (pioglitazone hydrochloride) diabetes drug. Alphapharm had appealed to the high court to overturn an Appeals Court decision in favor of Takeda, but the Supreme Court declined to review the case, leaving the appeals court's decision final. The court outcome makes it unlikely U.S. FDA would approve Alphapharm's generic version of the drug. The Takeda patent on the drug expires in 2011. (Click here for more
You may also be interested in...
Abbott reported strong sales for diagnostics and devices in the third quarter and raised its full-year EPS guidance to $3.55 per share.
Vifor CEO Stefan Schulze tells Scrip that an expanded deal with Korsuva developer Cara Therapeutics means the US biotech will not have to invest in a commercial organization as the Swiss firm will mobilize its well-established sales force to launch the treatment for dialysis patients with CKD-associated pruritus.
A randomized trial demonstrated the superiority of Medtronic’s DTM spinal cord stimulation waveform over conventional spinal cord stimulation for treating back pain.